Cargando…

Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival

BACKGROUND: Seroprevalence of anti-SARS-CoV-2 antibodies is now available in several world regions to better estimate transmission dynamics. However, to date, there is no epidemiological data regarding anti-SARS-CoV-2 prevalence in Mexico. Therefore, we aimed to determine the prevalence of anti-SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Salazar, Cristina, Sánchez-García, Adriana, Rodríguez-Gutiérrez, René, Camacho-Ortiz, Adrián, Saldívar-Rodríguez, Donato, González-González, José Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374409/
https://www.ncbi.nlm.nih.gov/pubmed/34412620
http://dx.doi.org/10.1186/s12879-021-06550-5
_version_ 1783740110109409280
author Díaz-Salazar, Cristina
Sánchez-García, Adriana
Rodríguez-Gutiérrez, René
Camacho-Ortiz, Adrián
Saldívar-Rodríguez, Donato
González-González, José Gerardo
author_facet Díaz-Salazar, Cristina
Sánchez-García, Adriana
Rodríguez-Gutiérrez, René
Camacho-Ortiz, Adrián
Saldívar-Rodríguez, Donato
González-González, José Gerardo
author_sort Díaz-Salazar, Cristina
collection PubMed
description BACKGROUND: Seroprevalence of anti-SARS-CoV-2 antibodies is now available in several world regions to better estimate transmission dynamics. However, to date, there is no epidemiological data regarding anti-SARS-CoV-2 prevalence in Mexico. Therefore, we aimed to determine the prevalence of anti-SARS-CoV-2 antibodies and define the clinical and demographic characteristics associated with seroprevalence. METHODS: We conducted a cross-sectional serological survey in Ciudad Guadalupe, NL, Mexico. City government employees voluntarily participated during July 2020. Demographic and clinical characteristics were collected at the time of blood sampling to analyze the associated characteristics. IgM/IgG antibodies were determined using a qualitative chemiluminescent immunoassay. Descriptive statistics were used for categorical and continuous variables. Statistical significance was tested using the Chi-squared test, Student’s t-test and the Mann–Whitney. Logistic regression models and the odds ratios (adjusted and unadjusted) were used to estimate the association of demographic and clinical characteristics. RESULTS: Of the 3,268 participants included, 193 (5.9%, 95% CI 5.1–6.8) tested positive for IgM/IgG against SARS-CoV-2. Sex, city of residence, and comorbidities did not show any association with having IgM/IgG antibodies. A total of 114 out of 193 (59.1%) subjects with a positive test were asymptomatic, and the odds of being positive were higher in those who reported symptoms of COVID-19 in the previous four weeks to the survey (OR 4.1, 95% CI 2.9–5.5). CONCLUSIONS: There is a low rate of SARS-CoV-2 infection among government employees that have continuously been working during the pandemic. Six in ten infections were asymptomatic, and seroprevalence is low and still far from herd immunity. Epidemiological surveillance and preventive measures should be mandatory.
format Online
Article
Text
id pubmed-8374409
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83744092021-08-19 Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival Díaz-Salazar, Cristina Sánchez-García, Adriana Rodríguez-Gutiérrez, René Camacho-Ortiz, Adrián Saldívar-Rodríguez, Donato González-González, José Gerardo BMC Infect Dis Research Article BACKGROUND: Seroprevalence of anti-SARS-CoV-2 antibodies is now available in several world regions to better estimate transmission dynamics. However, to date, there is no epidemiological data regarding anti-SARS-CoV-2 prevalence in Mexico. Therefore, we aimed to determine the prevalence of anti-SARS-CoV-2 antibodies and define the clinical and demographic characteristics associated with seroprevalence. METHODS: We conducted a cross-sectional serological survey in Ciudad Guadalupe, NL, Mexico. City government employees voluntarily participated during July 2020. Demographic and clinical characteristics were collected at the time of blood sampling to analyze the associated characteristics. IgM/IgG antibodies were determined using a qualitative chemiluminescent immunoassay. Descriptive statistics were used for categorical and continuous variables. Statistical significance was tested using the Chi-squared test, Student’s t-test and the Mann–Whitney. Logistic regression models and the odds ratios (adjusted and unadjusted) were used to estimate the association of demographic and clinical characteristics. RESULTS: Of the 3,268 participants included, 193 (5.9%, 95% CI 5.1–6.8) tested positive for IgM/IgG against SARS-CoV-2. Sex, city of residence, and comorbidities did not show any association with having IgM/IgG antibodies. A total of 114 out of 193 (59.1%) subjects with a positive test were asymptomatic, and the odds of being positive were higher in those who reported symptoms of COVID-19 in the previous four weeks to the survey (OR 4.1, 95% CI 2.9–5.5). CONCLUSIONS: There is a low rate of SARS-CoV-2 infection among government employees that have continuously been working during the pandemic. Six in ten infections were asymptomatic, and seroprevalence is low and still far from herd immunity. Epidemiological surveillance and preventive measures should be mandatory. BioMed Central 2021-08-19 /pmc/articles/PMC8374409/ /pubmed/34412620 http://dx.doi.org/10.1186/s12879-021-06550-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Díaz-Salazar, Cristina
Sánchez-García, Adriana
Rodríguez-Gutiérrez, René
Camacho-Ortiz, Adrián
Saldívar-Rodríguez, Donato
González-González, José Gerardo
Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival
title Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival
title_full Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival
title_fullStr Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival
title_full_unstemmed Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival
title_short Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival
title_sort prevalence and associated characteristics of anti-sars-cov-2 antibodies in mexico 5 months after pandemic arrival
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374409/
https://www.ncbi.nlm.nih.gov/pubmed/34412620
http://dx.doi.org/10.1186/s12879-021-06550-5
work_keys_str_mv AT diazsalazarcristina prevalenceandassociatedcharacteristicsofantisarscov2antibodiesinmexico5monthsafterpandemicarrival
AT sanchezgarciaadriana prevalenceandassociatedcharacteristicsofantisarscov2antibodiesinmexico5monthsafterpandemicarrival
AT rodriguezgutierrezrene prevalenceandassociatedcharacteristicsofantisarscov2antibodiesinmexico5monthsafterpandemicarrival
AT camachoortizadrian prevalenceandassociatedcharacteristicsofantisarscov2antibodiesinmexico5monthsafterpandemicarrival
AT saldivarrodriguezdonato prevalenceandassociatedcharacteristicsofantisarscov2antibodiesinmexico5monthsafterpandemicarrival
AT gonzalezgonzalezjosegerardo prevalenceandassociatedcharacteristicsofantisarscov2antibodiesinmexico5monthsafterpandemicarrival